Close

CymaBay Therapeutics (CBAY) Announces Oral Late-Breaking Presentation of Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With PBC at AASLD

Go back to CymaBay Therapeutics (CBAY) Announces Oral Late-Breaking Presentation of Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With PBC at AASLD
CAL-BAY INTL (NASDAQ: CBAY) Delayed: 32.48 --0 (-0%)
Previous Close $32.48    52 Week High $3.04 
Open $32.48    52 Week Low $0.82 
Day High $32.48    P/E N/A 
Day Low $32.48    EPS $0.00 
Volume 27,030